Heart Diseases

Cardiovascular disease, including heart disease and stroke, is a major global health concern and the leading cause of death and disability worldwide. At Boehringer Ingelheim, we address unmet medical need by providing innovative treatments that aim to improve the holistic care of patients living with a range of cardiovascular conditions, including heart failure, irregular heartbeat (atrial fibrillation), stroke, blood clots in deep veins or lungs (deep vein thrombosis or pulmonary embolism), high blood pressure (hypertension) or heart attack (myocardial infarction).

The cardiovascular system is intricately linked with the renal and metabolic systems, and an ever-growing body of clinical data shows that diseases affecting one of these systems often exert negative effects on the others, resulting in the progression of diseases such as type 2 diabetes, heart failure and chronic kidney disease. In fact, the majority of deaths among people with chronic kidney disease and/or diabetes occur as a result of cardiovascular disease. Conversely, improving the health of one system can lead to positive effects across the others and can help reduce the risk for further complications. Through research and treatments, with our partner, Eli Lilly and Company, Boehringer Ingelheim is working to help those whose health is jeopardized by these conditions.